Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | BIV1-CovIran[1] COVIran Barakat COVIran Barkat کووایران برکت |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
Full and emergency authorizations Full list of COVIran Barekat authorizations |
Identifiers | |
CAS Number |
COVIran Barekat[3] (Persian: کووایران برکت) is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group.[4][5][6] It is an inactivated virus-based vaccine.[3] Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East.[7]
Officials in charge say they are in the process to publish the results of the clinical trials in a peer-reviewed journal.[8] The interim results of the phases 1 and 2 trials showed 93.5% (95% CI, 88.4–99.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2.[9] Those results have not been peer-reviewed and describe the immunogenicity of the vaccine and not its efficacy. On 3 March 2022, peer-reviewed results have been published in the Clinical Microbiology and Infection.[10] [further explanation needed]
As of February 27, 2022, approximately 60 million doses have been produced according to Shifa Pharmed's CEO.[11] and the annual production capacity of this vaccine has reached 350 million doses.[12] Multiple Iranian personalities have received the vaccine, including the Supreme Leader, Ali Khamenei[5] and the President, Ebrahim Raisi.[13]
A version of the vaccine based on the Omicron variant and named CovIran Barkat Plus is in development and studied to be given as a third dose.[14][15]
:10
was invoked but never defined (see the help page).Tasnim_2021
was invoked but never defined (see the help page).:15
was invoked but never defined (see the help page).:21
was invoked but never defined (see the help page).